SLN - Is This A Miracle Drug For 'Sticky Cholesterol'? Analysts Applaud Safety Efficacy Of Silence Therapeutics' Heart Disease Candidate | Benzinga
Earlier today, Silence Therapeutics plc (NASDAQ: SLN) announced topline results from the multiple-dose component of the APOLLO phase 1 study of zerlasiran (formerly SLN360) in 36 adults with baseline lipoprotein(a) (Lp(a), levels at or over 150 nmol/L and stable atherosclerotic cardiovascular disease (ASCVD).
The data demonstrated a significant reduction from baseline in Lp(a) of up to 99% at 90 days following injection of repeated doses. Lp(a) levels remained approximately 90% lower than baseline at 201 days (end of treatment period) at ...